Heron Therapeutics (HRTX) Tops Q3 EPS by 12c

Heron Therapeutics (NASDAQ: HRTX) reported Q3 EPS of ($0.17), $0.12 better than the analyst estimate of ($0.29). Revenue for the quarter came in at $31.43 million versus the consensus estimate of $32.75 million.

For earnings history and earnings-related data on Heron Therapeutics (HRTX) click here.

You May Also Be Interested In

• Oracle (ORCL) Tops Q1 EPS by 19c, Beats on Revenue; Beats on Cloud Revenue, Offers Q3 EPS Guidance
• IBEX Limited (IBEX) Tops Q4 EPS by 6c; offers guidance
• Copart to buy ACV for $1.9 billion in cash deal